Center for Dietary Supplements and Inflammation

膳食补充剂和炎症中心

基本信息

项目摘要

DESCRIPTION (provided by applicant): This COBRE application proposes to establish a Center for Dietary Supplements and Inflammation (CDSI) at the University of South Carolina (USC) that will pursue multidisciplinary research on how botanicals can modulate inflammation and be used to prevent and/or treat inflammatory diseases. Recently, USC has made significant strides to promote research in Complementary and Alternative Medicine (CAM) which has resulted in the award of a Program Project/Center grant to study CAM modalities to treat autoimmune diseases. Thus, the CDSI will complement the CAM program and create a unique niche at USC in inflammation research. The main goal of CDSI is to establish multi-disciplinary research that will identify the molecular mechanisms through which botanicals modulate inflammation so that they or their analogs can be used to prevent and/or treat inflammatory diseases. Americans spend~$33.9 billion/year on CAM, of which ~$20 billion is on dietary supplements. It is becoming increasingly clear that inflammation plays a critical role in the pathogenesis of not only autoimmune diseases but also a wide range of clinical disorders including cardiovascular diseases, neurodegenerative disorders, and cancer: areas under investigation in this study. Thus, understanding the mode of action of dietary supplements or their constituents on inflammation, could lead to novel treatment modalities with far ranging clinical implications. The CDSI goal will be accomplished through promotion of multi-disciplinary research pursued by 4 junior tenure-track faculty in the area of inflammatory diseases, through highly structured mentoring by eight senior faculty members, and providing them with state-of-the-art core facilities. The program will be evaluated by an External Advisory Committee consisting of nationally recognized scientists. Additionally, through institutional support, 10 new tenure-track junior faculty will be recruited and trained at USC to bolster and advance inflammation research. The long term objective of the CDSI would be to build a self-sustaining, nationally recognized multi-disciplinary Center for dietary supplements and inflammation research, by promoting innovation, faculty entrepreneurship, collaborative research projects (PPGs and Institutional Training grants), and clinical/translational research.
描述(由申请人提供):本COBRE申请建议在南卡罗来纳州大学(USC)建立膳食补充剂和炎症中心(CDSI),该中心将对植物如何调节炎症并用于预防和/或治疗炎症性疾病进行多学科研究。最近,南加州大学在促进补充和替代医学(CAM)的研究方面取得了重大进展,这导致了一项计划项目/中心赠款的授予,以研究CAM治疗自身免疫性疾病的方式。因此,CDSI将补充CAM计划,并在南加州大学炎症研究中创造一个独特的利基。CDSI的主要目标是建立多学科研究,以确定植物调节炎症的分子机制,以便它们或其类似物可用于预防和/或治疗炎症性疾病。美国人每年在CAM上花费约339亿美元,其中约200亿美元用于膳食补充剂。越来越清楚的是,炎症不仅在自身免疫性疾病的发病机制中起着关键作用,而且在包括心血管疾病、神经退行性疾病和癌症在内的广泛的临床疾病中也起着关键作用:本研究正在研究的领域。因此,了解膳食补充剂或其成分对炎症的作用方式,可能会导致具有广泛临床意义的新型治疗方式。CDSI的目标将通过促进4名初级终身教职员工在炎症性疾病领域进行的多学科研究来实现,通过8名高级教师的高度结构化指导,并为他们提供最先进的核心设施。该计划将由一个由国家认可的科学家组成的外部咨询委员会进行评估。此外,通过机构支助, 南加州大学将招募和培训终身教职的初级教师,以支持和推进炎症研究。CDSI的长期目标是通过促进创新,教师创业,合作研究项目(PPG和机构培训补助金)和临床/转化研究,建立一个自我维持的,国家认可的多学科膳食补充剂和炎症研究中心。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prakash S Nagarkatti其他文献

Prakash S Nagarkatti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Prakash S Nagarkatti', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10428525
  • 财政年份:
    2012
  • 资助金额:
    $ 196.18万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10227907
  • 财政年份:
    2012
  • 资助金额:
    $ 196.18万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10830736
  • 财政年份:
    2012
  • 资助金额:
    $ 196.18万
  • 项目类别:
Center for Dietary Supplements and Inflammation
膳食补充剂和炎症中心
  • 批准号:
    8733726
  • 财政年份:
    2012
  • 资助金额:
    $ 196.18万
  • 项目类别:
Center for Dietary Supplements and Inflammation
膳食补充剂和炎症中心
  • 批准号:
    8216765
  • 财政年份:
    2012
  • 资助金额:
    $ 196.18万
  • 项目类别:
Immunopathological basis of PTSD
PTSD的免疫病理学基础
  • 批准号:
    8466380
  • 财政年份:
    2011
  • 资助金额:
    $ 196.18万
  • 项目类别:
Immunopathological basis of PTSD
PTSD的免疫病理学基础
  • 批准号:
    8167365
  • 财政年份:
    2011
  • 资助金额:
    $ 196.18万
  • 项目类别:
Immunopathological basis of PTSD
PTSD的免疫病理学基础
  • 批准号:
    8662798
  • 财政年份:
    2011
  • 资助金额:
    $ 196.18万
  • 项目类别:
Immunopathological basis of PTSD
PTSD的免疫病理学基础
  • 批准号:
    8277881
  • 财政年份:
    2011
  • 资助金额:
    $ 196.18万
  • 项目类别:
Use of Resveratrol to treat experimental multiple sclerosis
使用白藜芦醇治疗实验性多发性硬化症
  • 批准号:
    7394180
  • 财政年份:
    2007
  • 资助金额:
    $ 196.18万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 196.18万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 196.18万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 196.18万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 196.18万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 196.18万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 196.18万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 196.18万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 196.18万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 196.18万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 196.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了